BGC
PTCT icon

Blue Granite Capital’s PTC Therapeutics PTCT Stock Holding History

Blue Granite Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-58,000
Closed -$571K – 115
2017
Q1 		$571K Hold
58,000
– – 0.37% 61
2016
Q4 		$633K Buy
+58,000
New +$608K 0.45% 59

Other funds holding PTCT

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Blue Granite Capital's PTCT Position: Q2 2017 in Review

Blue Granite Capital sold out of PTC Therapeutics (PTCT) in Q2 2017, closing a stake of 58,000 shares — an estimated $571K sold.

Blue Granite Capital first reported a position in PTCT in Q4 2016 and held it in 2 quarters. The position peaked at $633K in Q4 2016. 114 funds tracked by Wall St. Rank hold PTCT as of Q2 2017.

  • Blue Granite Capital reported no remaining PTC Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Blue Granite Capital sold 58,000 PTC Therapeutics shares in Q2 2017, an estimated $571K.
  • Blue Granite Capital first reported a position in PTC Therapeutics in Q4 2016 and held it in 2 quarters.
  • Blue Granite Capital's PTC Therapeutics position peaked at $633K in Q4 2016.
  • 114 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2017.

Based on Blue Granite Capital's 13F filing for Q2 2017, filed 17 Jul 2017.